Northland Securities Initiates Coverage on Bio-Rad (BIO) with an Outperform
BIO Hot Sheet
Rating Summary:0 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Northland Securities initiates coverage on Bio-Rad Laboratories (NYSE: BIO) with an Outperform. Price target $88.
To see more analyst ratings on BIO Click Here.
Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
To see more analyst ratings on BIO Click Here.
Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
New CoverageRelated Entities
Northland SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
